neoadjuvant immunotherapy of locally advanced upper urinary tract urothelial carcinoma

Showing 1 - 1 of 1

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Neoadjuvant Immunotherapy of Locally Advanced Upper Urinary Tract Urothelial Carcinoma Trial in Shanghai (Tislelizumab)

Active, not recruiting
  • Neoadjuvant Immunotherapy of Locally Advanced Upper Urinary Tract Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Dec 12, 2020